Cardiovascular Kidney and Metabolic Health Assessment and Patient Empowerment
NCT07403669
Summary
The primary objective of CHAPERONE solution is to evaluate the efficacy of engaging, assessing, and enabling long term treatment strategy with Health Artificial Intelligence (AI) Chatbot, Copilot, Large Language Model (LLM) and vital sign monitoring device in reducing CKM disease burden using an algorithm obtained from biomarkers and diagnostics utilizing remote sensor driven technology tools, care coordination and patient empowerment.
Eligibility
Inclusion Criteria: * Men and women over 18 years of age are included * Eligible subjects must have one of the risk factor/ disease component of CKM: * Diabetes with A1C of 7.5 or higher; * or Heart disease with stent placement; * or Coronary Artery Bypass Graft (CABG) in the last 12 months; * or Chronic Kidney Disease (CKD) stage 2- 4 * and, in those with Heart failure, a recent hospitalization within one week of enrollment is required Exclusion Criteria: * Those subjects who are not willing to sign an informed consent
Conditions6
Locations4 sites
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
NCT07403669